Mode
Text Size
Log in / Sign up
N/A N=53

Natural History Study in Subjects With Usher Syndrome

Usher Syndrome, Type 1B

Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: BCVA - Better Seeing Eyes — -2.26 ETDRS score — p=<0.01

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Pediatric, Adult, Older Adult · 8+ yrs
Sex
All
Sponsor
Fondazione Telethon
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
BCVA - Better Seeing Eyes
-1.468 <0.01 sig
PRIMARY
BCVA - Better Seeing Eyes
-1.468 <0.01 sig
PRIMARY
III4e Area - Better Seeing Eyes
70.286 0.4265
PRIMARY
III4e Area - Better Seeing Eyes
70.286 0.4265
PRIMARY
V4e Area - Better Seeing Eyes
700.245 0.2716
PRIMARY
V4e Area - Better Seeing Eyes
700.245 0.2716
PRIMARY
BCVA - Worse Seeing Eyes
-0.909 0.2677
PRIMARY
BCVA - Worse Seeing Eyes
-0.909 0.2677
PRIMARY
III4e Area - Worse Seeing Eyes
-407.928 0.1124
PRIMARY
III4e Area - Worse Seeing Eyes
-407.928 0.1124
PRIMARY
V4e Area - Worse Seeing Eyes
610.017 0.216
PRIMARY
V4e Area - Worse Seeing Eyes
610.017 0.216
SECONDARY
MS - Better Seeing Eyes
-0.315 0.7889
SECONDARY
MS - Better Seeing Eyes
-0.315 0.7889
SECONDARY
CMT - Better Seeing Eyes
-5.667 0.5092
SECONDARY
CMT - Better Seeing Eyes
-5.667 0.5092
SECONDARY
EZ Band Horizontal - Better Seeing Eyes
-160.556 0.0677
SECONDARY
EZ Band Horizontal - Better Seeing Eyes
-160.556 0.0677
SECONDARY
EZ Band Vertical - Better Seeing Eyes
190.553 0.3148
SECONDARY
EZ Band Vertical - Better Seeing Eyes
190.553 0.3148
SECONDARY
MS - Worse Seeing Eyes
-0.758 0.7196
SECONDARY
MS - Worse Seeing Eyes
-0.758 0.7196
SECONDARY
CMT - Worse Seeing Eyes
-2.026 0.4224
SECONDARY
CMT - Worse Seeing Eyes
-2.026 0.4224
SECONDARY
EZ Band Horizontal - Worse Seeing Eyes
-21.658 0.1461
SECONDARY
EZ Band Horizontal - Worse Seeing Eyes
-21.658 0.1461
SECONDARY
EZ Band Vertical - Worse Seeing Eyes
-15.861 0.0901
SECONDARY
EZ Band Vertical - Worse Seeing Eyes
-15.861 0.0901

Summary

Natural History Study in Subjects With Usher Syndrome ((USH1B) is a multi-centre, longitudinal, observational study designed to evaluate disease progression in subjects with USH1B by several vision-related assessments.

Eligibility Criteria

Inclusion Criteria

  • Must be willing to adhere to protocol for long-term follow-up as evidenced by written informed consent or parental permission and subject assent.
  • Subjects diagnosed with USH1.
  • Molecular diagnosis of USH1B due to MYO7A mutations (homozygotes or compound heterozygotes).
  • Age eight years old or older at the time of baseline.
  • Visual acuity ≥ 20/640 in at least one eye

Exclusion Criteria

  • Unable or unwilling to meet requirements of the study.
  • Unable to communicate with suitable verbal/auditory and/or tactile sign language (in the opinion of the investigator)
  • Participation in a clinical study with an investigational drug in the past six months.
  • Pre-existing eye conditions that would interfere with the interpretation of study endpoints (for example, glaucoma, corneal or significant lenticular opacities, cystoid macular oedema, macular hole).
  • Complicating systemic diseases in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example, radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Also excluded would be subjects with immuno- compromising diseases, as there could be susceptibility to opportunistic infection [such as cytomegalovirus (CMV) retinitis].
  • Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g. macular edema or proliferative changes).
  • Prior ocular surgery within three months.
  • Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03814499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search